Navigation Links
Intra-Cellular Therapies Cleared for Quotation on OTCQB
Date:12/19/2013

NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that its common stock has been approved for quotation on the OTC Markets – OTCQB tier (OTCQB) under the symbol "ITCI", and is expected to begin trading on December 20, 2013.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS").  The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia and other neuropsychiatric and neurological disorders.  In December 2013, the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia.  In this study, ITI-007 met the trial's pre-specified primary endpoint, improving symptoms associated with schizophrenia as measured by a statistically significant and clinically meaningful decrease in the Positive and Negative Syndrome Scale (PANSS) total score.  The trial also met key secondary outcome measures related to efficacy on PANSS subscales and safety. In the Phase II trial, ITI-007 exhibited a differentiating response profile across a broad range of symptoms that we believe is consistent with improvements in social functioning deficits.

The Company is also developing other drug candidates.  In February 2011, the Company entered into a collaboration with the Takeda Pharmaceutical Company to develop certain phosphodiesterase 1 (PDE1) inhibitors for the treatment of cognitive deficits in schizophrenia and other CNS disorders.  In February 2013, the Company announced the successful completion of a Phase I single rising dose study of the lead
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
2. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
3. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
4. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
5. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
6. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
7. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
8. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
9. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
10. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
11. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Medical, Inc. (Nasdaq: AEMD ), today announced that ... the Rodman & Renshaw 17th Annual Global Investment Conference in ... ET on Thursday, September 10, 2015. The presentation ... webcast which can be accessed by visiting the investor relations ... The webcast will be archived for thirty days.  ...
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... Finkelstein , President and Chief Executive Officer, will ... Renshaw Global Investment Conference, sponsored by H.C. ... held September 8-10, 2015 at the St. Regis ...
(Date:9/2/2015)... MENLO PARK, Calif. , Sept. 2, 2015 ... company today announced that Jim Pekarsky , chief executive ... & Renshaw 17th Annual Global Investment Conference taking place, September ... York . Mr. Pekarsky is scheduled to ... in Astor Suite A (2 nd floor). ...
Breaking Medicine Technology:RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
... Dec. 6, 2011 The US Oncology Network announced ... York Oncology Hematology , and J. Russell Hoverman , M.D., ... on value-based reimbursement and its impact on the future of cancer ... 1:00 p.m. ET/ 12 p.m. CT/ 11 a.m. MT/ 10 a.m. ...
... Chairman, Mr. E. Thomas Arington, announced today that Mr. ... and chief executive officer of Prasco.  He also announced ... chief operating officer, Mr. David Furniss as chief financial ... ventures. "I am extremely pleased to ...
Cached Medicine Technology:The US Oncology Network to Present Webinar on Value-Based Reimbursement 2Prasco Announces New, Expanded Roles for Key Executives 2
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an innovative ... its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone app ... A leader in health technology, RxNT was one of the first to build ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healtec® LLC hired ... departure of Kristen Dietz, former Chief Operations Officer. Shaun Carpenter MD, FAPWCA, ... welcoming Mr. Salot: “ Stanley H. Salot Jr , our new President and ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... its latest addition to its screen mirroring and extending product line -- ... Display, which operates in local WIFI setting, the new Splashtop Wired XDisplay delivers ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... a large stream of mixed documents that include EOBs, payments, and payment related ... extracting the data needed to reconcile their billing, with one efficient process and ...
(Date:9/2/2015)... ... September 02, 2015 , ... Density measurement ... final products. Automating sample handling makes density measurements more efficient and error-free. The ... of the automated workflow and the advantages compared to manual sample handling. , ...
Breaking Medicine News(10 mins):Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:Healtec® Announces Executive Leadership Change 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3
... Today, Tuesday, January 27, 2009, 9:30 A.M.** Elected ... Community Based Health System for Embracing Courageous New Direction ... Accord Includes Free and Fair Union ... Conference to announce historic hospital accords. WHEN: Today, ...
... seize billions from state, construct prison health care centers ... lawsuit was filed this week to prevent a federal ... dollars from California,s treasury for the sole purpose of ... Safe Ventura County opposes the proposal to construct seven ...
... Fitness Industry Leader Champions Gupta,s Commitment to Enriching Quality ... 27 The American Council on Exercise (ACE), America,s ... fitness certification, education and training organizations in the world, ... Dr. Sanjay Gupta , chief medical correspondent for the ...
... (NYSE: SGP ) today reported that it ... study, a pivotal Phase III study in treatment-naive patients. ... III study in patients who failed prior treatment that ... enrolled its registration studies for boceprevir, its lead investigational ...
... (NYSE Alternext US: ILI) today announced that the Company has ... "Exchange") that outlines the Company,s strategy to regain compliance with ... Exchange to formally respond to the submitted plan within 45 ... able to continue its listing up to June 23, 2010 ...
... ANTHEM, Ariz., Jan. 27 Prime Companies, Inc. ... , The Company has begun receiving income ... , The web site is now accessible ... , , "These are major achievements and ...
Cached Medicine News:Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 2Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 3Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 4Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 5Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 6Health News:Ventura County Taxpayers' Group Files Suit to Stop State-of-the-Art Hospitals for Incarcerated Felons 2Health News:American Council on Exercise (ACE) Endorses Appointment of Dr. Sanjay Gupta as Surgeon General of the United States 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 3Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 4Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 5Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 6Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 7Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 8Health News:Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards 2Health News:Prime Companies Revenue Stream Begins; Dentists in Every City and Town Available on Company's New Web Site 2
Expressions lets you change your eye color with lenses that offer incredible comfort and outstanding vision quality. Expression color lenses use a technologically advanced tinting process to produce ...
Modern, innovative and quick Intense Pulsed Light system. The Flash 1 is light and very compact, thus easily portable. Available in two different colors....
... for the physician who wishes to offer ... of clinical applications. The innovative cooled Nd:YAG ... treaent of deeper lying veins. The IPL ... and pigmented lesions, including IPL Skin Treaents ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Medicine Products: